A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Irreversible cell growth arrest, a process termed cellular senescence, is emerging as an intrinsic tumor suppressive mechanism. Oncogene-induced senescence is thought to be invariably preceded by hyperproliferation, aberrant replication, and activation of a DNA damage checkpoint response (DDR), rendering therapeutic enhancement of this process unsuitable for cancer treatment. We previously demonstrated in a mouse model of prostate cancer that inactivation of the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (Pten) elicits a senescence response that opposes tumorigenesis. Here, we show that Pten-loss-induced cellular senescence (PICS) represents a senescence response that is distinct from oncogene-induced senescence and can be targeted for cancer therapy. Using mouse embryonic fibroblasts, we determined that PICS occurs rapidly after Pten inactivation, in the absence of cellular proliferation and DDR. Further, we found that PICS is associated with enhanced p53 translation. Consistent with these data, we showed that in mice p53-stabilizing drugs potentiated PICS and its tumor suppressive potential. Importantly, we demonstrated that pharmacological inhibition of PTEN drives senescence and inhibits tumorigenesis in vivo in a human xenograft model of prostate cancer. Taken together, our data identify a type of cellular senescence that can be triggered in nonproliferating cells in the absence of DNA damage, which we believe will be useful for developing a "pro-senescence" approach for cancer prevention and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although initially PTEN loss-induced cellular senescence was not associated with DDR activation40, it was later found to be associated with hyperproliferation, DDR engagement and cellular senescence in vivo41”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“However, despite this, DDR markers have a limited potential for identifying senescent cells in vivo since DDR independent mechanisms are also capable of inducing senescence via p53/p21WAF1/CIP1 pathway (Alimonti et al., 2010; Freund et al., 2011; Muñoz-Espín et al., 2013; Storer et al., 2013; Salama et al., 2014).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Alimonti et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“pharmacological inhibition of PTEN in prostate cancer that is wild type for TP53, results in the inhibition of tumorigenesis with senescence induction in a human xenograft model 152”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“TP53 up-regulation upon PTEN inhibition appears to be dependent on mTOR activity, which increases TP53 translation 152”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“unlike OIS, PICS occurs in the absence of transient hyper-proliferation and a DNA damage response (DDR) 152”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [152]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Small molecule–based reversible reprogramming of cellular lifespan
Won, J., Kim, M. K., Kim, N., Ahn, J. H., Lee, W. G., Kim, S. S., Chang, K.-Y., Yi, Y.-W., & Kim, T. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio800 · Cited by 74
RetractedJemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Research works printed but not linked: 5
- Teng, 1997, Cancer Res., 57, 5221
- Bookstein, 1993, Cancer Res., 53, 3369
- Chen, 2009, Sci Signal., 2, ra44
- Roninson, 2003, Cancer Res., 63, 2705
- Arava, 2003, Methods Mol Biol., 224, 79
Cited by
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
Rubinsztein, D. C., Mariño, G., & Kroemer, G. (2011) · Cell · doi:10.1016/j.cell.2011.07.030 · Cited by 2,107
“PICS depends on the activation or mTOR and can be potentiated by inhibition of MDM2, which leads to an increase in p53 expression (Alimonti et al., 2010) and can be expected to inhibit autophagy (Tasdemir et al., 2008).”
BackgroundFour faces of cellular senescence
Rodier, F., & Campisi, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009094 · Cited by 2,070
“Cells also senesce without a DDR upon loss of the Pten tumor suppressor, a phosphatase that counteracts pro-proliferative/pro-survival kinases (Alimonti et al., 2010).”
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Self-citationMechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
Senescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
“Analysis of senescence markers in human cancer biopsies from patients previously exposed to neoadjuvant chemotherapy confirmed the occurrence of TIS and its association to treatment outcome (12, 293, 316, 321).”
BackgroundSelf-citationMechanisms and functions of cellular senescence
Herranz, N., & Gil, J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95148 · Cited by 1,232
Cellular senescence: the good, the bad and the unknown
Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L., & Lerman, L. O. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00601-z · Cited by 1,150
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Lee, Y.-R., Chen, M., & Pandolfi, P. P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0015-0 · Cited by 917
Self-citationSenescence and apoptosis: dueling or complementary cell fates?
Childs, B. G., Baker, D. J., Kirkland, J. L., Campisi, J., & van Deursen, J. M. (2014) · The EMBO Reports · doi:10.15252/embr.201439245 · Cited by 915
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Cellular senescence and its effector programs
Salama, R., Sadaie, M., Hoare, M., & Narita, M. (2014) · Genes & Development · doi:10.1101/gad.235184.113 · Cited by 855
Therapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824
“Raf1 Mitogenic/stress signaling + (26) MAP2K6/p38 Mitogenic/stress signaling + (27) Aurora kinase A Mitogenic signaling + (28) PTEN Oncogenic stress signaling + (29) SKP2 Mitogenic/stress signaling (30) Major tumor suppressors”
BackgroundInfluentialSenescence and aging: the critical roles of p53
Rufini, A., Tucci, P., Celardo, I., & Melino, G. (2013) · Oncogene · doi:10.1038/onc.2012.640 · Cited by 798
The metabolic roots of senescence: mechanisms and opportunities for intervention
Wiley, C. D., & Campisi, J. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00483-8 · Cited by 691
Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives
Baker, D. J., & Petersen, R. C. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95145 · Cited by 514
A continuum model for tumour suppression
Berger, A. H., Knudson, A. G., & Pandolfi, P. P. (2011) · Nature · doi:10.1038/nature10275 · Cited by 501
Self-citationCheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke-Hale, K., Dyer, M. D., Zhang, F., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0039 · Cited by 470
Inside and out: the activities of senescence in cancer
Pérez-Mancera, P. A., Young, A. R. J., & Narita, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3773 · Cited by 462
Pro-senescence therapy for cancer treatment
Nardella, C., Clohessy, J. G., Alimonti, A., & Pandolfi, P. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3057 · Cited by 437
Self-citationSenescence-associated inflammatory responses: aging and cancer perspectives
Lasry, A., & Ben-Neriah, Y. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.009 · Cited by 408
Aging Biomarker Consortium, Bao, H., Cao, J., Chen, M., Chen, M., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 376
Self-citationTumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388
Self-citationTranslating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
“PTEN loss induces a novel type of cellular senescence, referred to as PICS ( PTEN -loss induced cellular senescence), which can prevent prostate tumorigenesis and induce the immune system to directly target tumor cells”
BackgroundNuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner
Song, M. S., Carracedo, A., Salmena, L., Song, S. J., Egia, A., Malumbres, M., & Pandolfi, P. P. (2011) · Cell · doi:10.1016/j.cell.2010.12.020 · Cited by 376
Self-citationSenescent cells and osteoarthritis: a painful connection
Jeon, O. H., David, N., Campisi, J., & Elisseeff, J. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95147 · Cited by 356
Choi, N., Zhang, B., Zhang, L., Ittmann, M., & Xin, L. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.005 · Cited by 341
Astle, M. V., Hannan, K. M., Ng, P. Y., Lee, R. S., George, A. J., Hsu, A. K., Haupt, Y., Hannan, R. D., & Pearson, R. B. (2012) · Oncogene · doi:10.1038/onc.2011.394 · Cited by 295
“…will target both mTORC2-dependent AKT activation and mTORC1-dependent growth (Feldman et al., 2009; Dowling et al., 2010; Hsieh et al., 2010), dual PI3K/mTOR inhibitors (Bhatt et al., 2010) or the use of the MDM2 antagonist Nutlin-3a in combination with mTOR inhibition (Alimonti et al., 2010b).”
BackgroundInfluentialEmerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence
Xu, Y., Li, N., Xiang, R., & Sun, P. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.04.004 · Cited by 282
Plzf Regulates Germline Progenitor Self-Renewal by Opposing mTORC1
Hobbs, R. M., Seandel, M., Falciatori, I., Rafii, S., & Pandolfi, P. P. (2010) · Cell · doi:10.1016/j.cell.2010.06.041 · Cited by 273
Self-citationA metabolic prosurvival role for PML in breast cancer
Carracedo, A., Weiss, D., Leliaert, A. K., Bhasin, M., de Boer, V. C. J., Laurent, G., Adams, A. C., Sundvall, M., Song, S. J., Ito, K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62129 · Cited by 269
Self-citationAbrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Vredeveld, L. C. W., Possik, P. A., Smit, M. A., Meissl, K., Michaloglou, C., Horlings, H. M., Ajouaou, A., Kortman, P. C., Dankort, D., McMahon, M., et al. (2012) · Genes & Development · doi:10.1101/gad.187252.112 · Cited by 262
Prostate carcinogenesis: inflammatory storms
de Bono, J. S., Guo, C., Gurel, B., De Marzo, A. M., Sfanos, K. S., Mani, R. S., Gil, J., Drake, C. G., & Alimonti, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0267-9 · Cited by 227
Self-citationIn vitro and in vivo model systems used in prostate cancer research
Cunningham, D., & You, Z. (2015) · Journal of Biological Methods · doi:10.14440/jbm.2015.63 · Cited by 229
Senescence: a new weapon for cancer therapy
Acosta, J. C., & Gil, J. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.11.006 · Cited by 223
Two-Step Senescence-Focused Cancer Therapies
Sieben, C. J., Sturmlechner, I., van de Sluis, B., & van Deursen, J. M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.006 · Cited by 222
p53, ROS and senescence in the control of aging
Vigneron, A., & Vousden, K. H. (2010) · Aging · doi:10.18632/aging.100189 · Cited by 221
“While mTOR is normally associated with cell growth, activation of mTOR can contribute to and be essential for certain types of senescence [11,12], and the maintenance of mTOR signalling under conditions of cell cycle arrest leads to senescence in cultured cells [13].”
BackgroundmTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
Zabala-Letona, A., Arruabarrena-Aristorena, A., Martín-Martín, N., Fernandez-Ruiz, S., Sutherland, J. D., Clasquin, M., Tomas-Cortazar, J., Jimenez, J., Torres, I., Quang, P., et al. (2017) · Nature · doi:10.1038/nature22964 · Cited by 214
Self-citationKennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.020 · Cited by 213
SASP: Tumor Suppressor or Promoter? Yes!
Rao, S. G., & Jackson, J. G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.001 · Cited by 206
Cellular senescence in cancer: from mechanisms to detection
Ou, H., Hoffmann, R., González‐López, C., Doherty, G. J., Korkola, J. E., & Muñoz‐Espín, D. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12807 · Cited by 190
Saito, Y., Chikenji, T. S., Matsumura, T., Nakano, M., & Fujimiya, M. (2020) · Nature Communications · doi:10.1038/s41467-020-14734-x · Cited by 196
Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer
Masetti, M., Carriero, R., Portale, F., Marelli, G., Morina, N., Pandini, M., Iovino, M., Partini, B., Erreni, M., Ponzetta, A., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210564 · Cited by 189
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 194
PTEN Tumor-Suppressor: The Dam of Stemness in Cancer
Luongo, F., Colonna, F., Calapà, F., Vitale, S., Fiori, M. E., & De Maria, R. (2019) · Cancers · doi:10.3390/cancers11081076 · Cited by 189
Chen, M., Pratt, C. P., Zeeman, M. E., Schultz, N., Taylor, B. S., O'Neill, A., Castillo-Martin, M., Nowak, D. G., Naguib, A., Grace, D. M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.013 · Cited by 177
Self-citationBasu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171
Nucleotide metabolism, oncogene-induced senescence and cancer
Aird, K. M., & Zhang, R. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.01.017 · Cited by 166
“Indeed, suppression of S-phase progression is sufficient to block RASinduced senescence [35].”
mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53
Jung, S. H., Hwang, H. J., Kang, D., Park, H. A., Lee, H. C., Jeong, D., Lee, K., Park, H. J., Ko, Y.-G., & Lee, J.-S. (2019) · Oncogene · doi:10.1038/s41388-018-0521-8 · Cited by 166
MOZ increases p53 acetylation and premature senescence through its complex formation with PML
Rokudai, S., Laptenko, O., Arnal, S. M., Taya, Y., Kitabayashi, I., & Prives, C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300490110 · Cited by 155
McCubrey, J. A., Rakus, D., Gizak, A., Steelman, L. S., Abrams, S. L., Lertpiriyapong, K., Fitzgerald, T. L., Yang, L. V., Montalto, G., Cervello, M., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.09.004 · Cited by 161
Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
Larsson, L. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.005 · Cited by 173
The role of cellular senescence and SASP in tumour microenvironment
Takasugi, M., Yoshida, Y., Hara, E., & Ohtani, N. (2023) · The FEBS Journal · doi:10.1111/febs.16381 · Cited by 144
Banasavadi-Siddegowda, Y. K., Russell, L., Frair, E., Karkhanis, V. A., Relation, T., Yoo, J. Y., Zhang, J., Sif, S., Imitola, J., Baiocchi, R., et al. (2017) · Oncogene · doi:10.1038/onc.2016.199 · Cited by 136
Butler, D. E., Marlein, C. R., Walker, H. F., Frame, F. M., Mann, V. M., Simms, M. S., Davies, B. R., Collins, A. T., & Maitland, N. J. (2017) · Oncotarget · doi:10.18632/oncotarget.18082 · Cited by 143
Cellular senescence and cancer chemotherapy resistance
Gordon, R. R., & Nelson, P. S. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.002 · Cited by 134
Turning Off AKT: PHLPP as a Drug Target
Newton, A. C., & Trotman, L. C. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140338 · Cited by 128
Self-citationAkt: a key transducer in cancer
Tsai, P., Lai, Y., Manne, R., Tsai, Y.-S., Sarbassov, D. D., & Lin, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00860-9 · Cited by 143
Laine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0292 · Cited by 130
Colucci, M., Sarill, M., Maddalena, M., Valdata, A., Troiani, M., Massarotti, M., Bolis, M., Bressan, S., Kohl, A., Robesti, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.015 · Cited by 164
Self-citationTightrope act: autophagy in stem cell renewal, differentiation, proliferation, and aging
Phadwal, K., Watson, A., & Simon, A. K. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1032-3 · Cited by 138
Haplo‐insufficiency: a driving force in cancer
Berger, A. H., & Pandolfi, P. P. (2011) · The Journal of Pathology · doi:10.1002/path.2800 · Cited by 124
Self-citationActivation of Lung p53 by Nutlin-3a Prevents and Reverses Experimental Pulmonary Hypertension
Mouraret, N., Marcos, E., Abid, S., Gary-Bobo, G., Saker, M., Houssaini, A., Dubois-Rande, J.-L., Boyer, L., Boczkowski, J., Derumeaux, G., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002434 · Cited by 123
Splicing-Factor Oncoprotein SRSF1 Stabilizes p53 via RPL5 and Induces Cellular Senescence
Fregoso, O. I., Das, S., Akerman, M., & Krainer, A. R. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.02.001 · Cited by 130
Mechanisms and significance of therapy-induced and spontaneous senescence of cancer cells
Mikuła-Pietrasik, J., Niklas, A., Uruski, P., Tykarski, A., & Książek, K. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03261-8 · Cited by 119
Cellular senescence: Neither irreversible nor reversible
Reimann, M., Lee, S., & Schmitt, C. A. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232136 · Cited by 134
Cellular senescence: a double-edged sword in cancer therapy
Xiao, S., Qin, D., Hou, X., Tian, L., Yu, Y., Zhang, R., Lyu, H., Guo, D. S., Chen, X., Zhou, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1189015 · Cited by 143
Prieur, A., Besnard, E., Babled, A., & Lemaitre, J.-M. (2011) · Nature Communications · doi:10.1038/ncomms1473 · Cited by 117
“The absence of DDR was also described in another type of senescence induction, Pten-loss-induced cellular senescence, but in this case, cellular senescence occurred in the absence of DNA replicatio”
BackgroundOncogene-induced senescence: From biology to therapy
Zhu, H., Blake, S., Kusuma, F. K., Pearson, R. B., Kang, J., & Chan, K. T. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111229 · Cited by 116
Molecular pathways and targets in prostate cancer
Shtivelman, E., Beer, T. M., & Evans, C. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2406 · Cited by 127
The Paradoxical Role of Cellular Senescence in Cancer
Yang, J., Liu, M., Hong, D., Zeng, M., & Zhang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.722205 · Cited by 114
Lunyak, V. V., Amaro-Ortiz, A., & Gaur, M. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00220 · Cited by 114
Cellular senescence: a promising strategy for cancer therapy
Lee, S., & Lee, J.-S. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.294 · Cited by 115
Senescent Cells and Their Secretory Phenotype as Targets for Cancer Therapy
Velarde, M. C., Demaria, M., & Campisi, J. (2013) · Interdisciplinary Topics in Gerontology and Geriatrics · doi:10.1159/000343572 · Cited by 112
“Importantly, PTEN-induced cellular senescence does not trigger a DNA damage response or hyperproliferative stage [57], which is typically induced by the activation of many oncogenes, and thus avoids an accumulation of damaged cells that can favor cancer progression.”
BackgroundBoominathan, L. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9257-9 · Cited by 120
Lan, R., Geng, H. Z., Polichnowski, A. J., Singha, P. K., Saikumar, P., McEwen, D. G., Griffin, K. A., Koesters, R., Weinberg, J. M., BIDANI, A. K., et al. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00660.2011 · Cited by 122
To clear, or not to clear (senescent cells)? That is the question
Lujambio, A. (2016) · BioEssays · doi:10.1002/bies.201670910 · Cited by 108
Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies
D’Ambrosio, M., & Gil, J. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.05.010 · Cited by 119
Brandmaier, A., Hou, S., & Shen, W. H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.06.004 · Cited by 120
PRMT5 as a druggable target for glioblastoma therapy
Banasavadi‐Siddegowda, Y., Welker, A. M., An, M. J., Yang, X. T., Zhou, W., Shi, G., Imitola, J., Li, C., Hsu, S. H., Wang, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox206 · Cited by 112
Detection and manipulation of phosphoinositides
Idevall-Hagren, O., & De Camilli, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.008 · Cited by 105
Wnt5a Suppresses Epithelial Ovarian Cancer by Promoting Cellular Senescence
Bitler, B. G., Nicodemus, J. P., Li, H., Cai, Q. K., Wu, H. G., Xiang, H., Li, T., Birrer, M. J., Godwin, A. K., Cairns, P., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1341 · Cited by 108
Cho, H., Herzka, T. M., Wu, Z., Qi, J., Wilkinson, J. E., Bradner, J. E., Robinson, B. D., Castillo-Martín, M., Cordon‐Cardo, C., & Trotman, L. C. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0346 · Cited by 107
Self-citationAndrogen regulation of prostate cancer: Where are we now?
Corona, G., Baldi, E., & Maggi, M. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03347072 · Cited by 108
Yuan, T. L., Wulf, G., Burga, L., & Cantley, L. C. (2011) · Current Biology · doi:10.1016/j.cub.2010.12.047 · Cited by 98
Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy
Triana-Martínez, F., Loza, M. I., & Domínguez, E. (2020) · Cells · doi:10.3390/cells9020346 · Cited by 95
Liu, H., Zhao, H., & Sun, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.004 · Cited by 108
Hallmarks of cellular senescence: biology, mechanisms, regulations
Ajoolabady, A., Praticò, D., Bahijri, S., Tuomilehto, J. O., Uversky, V. N., & Ren, J. T. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01480-7 · Cited by 121
Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells
Naguib, A., Mathew, G., Reczek, C. R., Watrud, K. E., Ambrico, A. J., Herzka, T. M., Casanova‐Salas, I., Lee, M. F., El-Amine, N., Zheng, W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.032 · Cited by 96
Self-citationZhang, F., Guo, J., Yu, S., Zheng, Y., Duan, M., Zhao, L., Wang, Y., Yang, Z., & Jiang, X. (2024) · 癌症:英文版 · doi:10.1002/cac2.12591 · Cited by 112
MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
Clegg, N. J., Couto, S. S., Wongvipat, J., Hieronymus, H., Carver, B. S., Taylor, B. S., Ellwood‐Yen, K., Gerald, W. L., Sander, C., & Sawyers, C. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017449 · Cited by 97
Deciphering the role of Nuclear Factor-κB in cellular senescence
Vaughan, S., & Jat, P. S. (2011) · Aging · doi:10.18632/aging.100390 · Cited by 86
Genetics of melanoma progression: the rise and fall of cell senescence
Bennett, D. C. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12422 · Cited by 85
Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer
Mitri, D. D., & Alimonti, A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.005 · Cited by 100
Self-citationMolecular damage in cancer: an argument for mTOR-driven aging
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100422 · Cited by 90
Metadata
- Authors
- Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., Rosivatz, E., Woscholski, R., Cognetti, F., Scher, H. I., & Pandolfi, P. P.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Cincinnati (US)
- Imperial College London (GB)
- Instituto Nazionale Tumori Regina Elena (IT)
- Corresponding author
- Pandolfi, Pier Paolo
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-03-01
- Volume
- 120
- Issue
- 3
- Pages
- 681-693
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2827955
- OpenAlex
- W2005250235
- Cited by
- 374
- References
- 46
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 23 · 2023: 12 · 2022: 24 · 2021: 18 · 2020: 30 · 2019: 17 · 2018: 27 · 2017: 17 · 2016: 20 · 2015: 20 · 2014: 28 · 2013: 25 · 2012: 27
- FWCI
- 23.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- American-Italian Cancer Foundation
- Associazione Italiana di Oncologia Medica
- National Institutes of Health
- National Cancer Institute (R01CA137050)
- National Institute on Minority Health and Health Disparities (R01MD004038)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, PTEN inactivation, prostate cancer, tumor suppression, DNA damage response, non-proliferating cells, tumor xenografts
- MeSH terms
- Animals, Disease Models, Animal, DNA Damage, Embryo, Mammalian, Fibroblasts, Humans, Male, Neoplasm Transplantation, Prostatic Neoplasms, Protein Biosynthesis, Transplantation, Heterologous, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Cellular Senescence, Mice, Knockout, Cell Line, Tumor, Cell Proliferation, PTEN Phosphohydrolase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.